Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 26, 2004

View Archived Issues

Highlights from the 12th Annual Biopartnering Europe conference now available on LifeSciChannel.com

New peptides with thrombin-inhibitory activity designed by Canadian scientists

Several series of PPAR agonists presented by Aventis researchers

Emerging companies showcased at the 12th Annual BioPartnering Europe conference: Alexza

Karo Bio presents new peptides modulating androgen receptors

Emerging companies showcased at the 12th Annual BioPartnering Europe conference: Allon Therapeutics

Novel IBAT inhibitors in early development at AstraZeneca

New antibacterial oxazolidinones patented by AstraZeneca

New mGluR5 antagonists prepared and tested at Addex

ARS scientists develop new prostanoid agonists for female infertility, asthma, etc.

Enrollment completed in phase II actinic keratosis study of Polyphenon E

Aricept ODT receives FDA approval

Two-year research program into macrolide development for TB

Positive opinion for Fendrix in Europe

European CHMP hands down positive opinion for Quintanrix

European Committee adopts extension of indication for Vfend

Peplin completes phase I study of PEP-005 Topical

Japanese approval for PegIntron in combination with Rebetol

New HCV studies unveiled for PegIntron in difficult-to-treat populations

Approvable letter for Thalomid sNDA for multiple myeloma

Tiagabine shows promise in anxiety and PTSD

Preclinical evidence for the antiapoptotic effects of tempol in the brain

Therapeutic benefits of lasofoxifene in menopausal vaginal atrophy

Synthesis of highly potent peptidomimetic beta-secretase inhibitors

Zonisamide reported effective and safe in children with epilepsy

Trypanocidal agent targets mitochondrial function in yeast

Glycine may represent a novel eradication therapy against drug-resistant H. pylori

Promising class of antibiotic agents against multiple antibiotic-resistant Gram-positive bacteria

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...